Trial Profile

A Phase 2 Study Evaluating Activity of Zenocutuzumab (MCLA-128) in Patients with or Without Molecularly Defined Cancers

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 09 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone acetate (Primary) ; Afatinib (Primary) ; Enzalutamide (Primary) ; Prednisone (Primary) ; Zenocutuzumab (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Prostate cancer
Focus Therapeutic Use
Sponsors Merus

Most Recent Events

18 Sep 2025 Status changed from active, no longer recruiting to discontinued.
28 Feb 2024 Status changed from recruiting to active, no longer recruiting, according to Merus media release.
28 Feb 2023 According to a Merus media release, the company plans to provide initial clinical data on Zeno in CRPC in the second half of 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com